Key result
The 5-year cumulative incidence of cardiovascular disease events following a breast cancer diagnosis was 5.8%, with HER-2 overexpression, stage III+ tumors, and pre-existing cardiovascular risk factors significantly increasing the risk.
Why the study?
Cardiovascular disease, particularly atrial fibrillation, is a growing concern in women with breast cancer, prompting the need to determine the incidence of cardiovascular events and identify risk factors.
Cohort (n=682)
No
Supports targeted CVD monitoring in breast cancer patients with HER-2 overexpression or advanced stage; hypothesis-generating for prospective intervention trials.
BACKGROUND: Concern for cardiovascular disease (particularly atrial fibrillation-AF) among women with breast cancer is becoming a major issue. We aimed at determining the incidence of cardiovascular disease events (AF, arterial and cardiac events, venous-thromboembolism-VTE) in patients diagnosed with breast cancer, and assessing potential risk factors. METHODS: We reviewed medical records of all patients diagnosed with breast cancer from 2010 to 2011 in our cancer center. Baseline characteristics of patients and tumors were collected. The main outcome was the occurrence of cardiovascular disease events (AF, VTE, arterial and cardiac events) during the 5-years follow-up. RESULTS: Among the 682 breast cancer patients, 22 (3.2%) patients had a history of atrial fibrillation. Thirty-four patients (5%) presented at least one cardiovascular disease event, leading to a cumulative incidence of 5.8% events at 5-years ([3.8-7.7] CI 95%), with most of them occurring in the first 2 years. AF cumulative incidence was 1.1% ([0.1-2.1] CI 95%). Factors associated with the occurrence of cardiovascular disease events (including AF) were an overexpression of HER-2 (HR 2.6 [1.21-5.56] p < 0.011), UICC-stage III tumors or more (HR 5.47 [2.78-10.76] p < 0.001) and pre-existing cardiovascular risk factors (HR 2.91 [1.36-6.23] p < 0.004). CONCLUSION: The incidence of cardiovascular disease events was 5.8% ([3.8-7.7] CI 95%), with HER-2 over-expression, UICC-stage III tumors or more and pre-existing cardiovascular diseases being associated with them. These findings call for the development of preventive strategies in patients diagnosed with breast cancer.
No takes yet. Share an insight, caveat, or question.
Méry et al. (2020) conducted a cohort in Breast cancer (n=682). Breast cancer was evaluated on Occurrence of cardiovascular disease events (atrial fibrillation, venous thromboembolism, arterial and cardiac events) during 5-years follow-up (95% CI 3.8-7.7). The 5-year cumulative incidence of cardiovascular disease events following a breast cancer diagnosis was 5.8%, with HER-2 overexpression, stage III+ tumors, and pre-existing cardiovascular risk factors significantly increasing the risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: